focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCoca-cola Euro. Regulatory News (CCEP)

Share Price Information for Coca-cola Euro. (CCEP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 69.00
Bid: 69.00
Ask: 69.60
Change: 0.00 (0.00%)
Spread: 0.60 (0.87%)
Open: 69.00
High: 0.00
Low: 0.00
Prev. Close: 69.00
CCEP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Letter to Shareholders

15 May 2020 10:30

RNS Number : 0488N
Coca-Cola European Partners plc
15 May 2020
 

Coca-Cola European Partners plc (CCEP or the Company)

 

15 May 2020

 

Dear Shareholder of Coca-Cola European Partners plc:

We are asking for your support in voting "FOR" all resolutions, as recommended by the Board of Directors, at our upcoming 2020 Annual General Meeting on 27 May 2020.

Certain proxy advisory services reports contain conflicting advice on Resolution 21 (Waiver of mandatory offer provisions set out in Rule 9 of the Takeover Code) and Resolutions 9 and 16 (regarding the re-election of Irial Finan and Mario Rotllant Solá respectively). Consequently, we believe it is important to provide additional context regarding these resolutions beyond that in our Notice of Meeting.

Resolution 21 (Waiver of mandatory offer provisions set out in Rule 9 of the Takeover Code)

The report from Glass, Lewis & Co. (Glass Lewis) recommends a vote "FOR" Resolution 21. The report from Institutional Shareholder Services (ISS) recommends a vote "AGAINST" Resolution 21. Both Glass Lewis and ISS have recommended voting "FOR" Resolutions 23 and 24 (Authorities to purchase own shares).

A share repurchase will not occur unless Resolution 21 is approved. Therefore, a vote "AGAINST" Resolution 21 will have the same effect as a vote "AGAINST" Resolutions 23 and 24.

The report from Glass Lewis states:

"We believe the terms of this proposal are reasonable. The Takeover Code was instituted as a shareholder safeguard in the event that a major shareholder sought a larger stake in the Company, possibly to the detriment of other shareholders.

In this case, we note that following a repurchase of shares or exercising of options, the concert party may increase their ownership stake in the Company but may not gain control of it without triggering a full takeover bid. Further, we note that the waiver will not apply to an acquisition of ordinary shares.

We do not believe that this proposal is connected with any sort of takeover attempt by this party, and thus, we do not believe this proposal should warrant shareholder concern at this time. We will, however, monitor the concert party's beneficial ownership in the event that a takeover attempt becomes more likely."

 

On the other hand, ISS recommends voting "AGAINST" Resolution 21 based on the application of its standard policy as a result of undefined "concerns over creeping control". This fails to take into account the purpose of Resolution 21 and Olive Partners, S.A.'s (Olive) stated intentions.

Rule 9 of the Takeover Code applies when any entity holds 30% or more of the voting rights of a company. When a company purchases its own voting shares, any resulting increase in the percentage of shares carrying voting rights will be an acquisition for the purpose of Rule 9. CCEP currently has one shareholder, Olive, which owns approximately 36% of our outstanding shares and so any share repurchase would automatically trigger Rule 9 of the Takeover Code and result in an obligation on Olive to make a general offer to shareholders for all the remaining equity share capital of CCEP. Therefore, the intention of Resolution 21 is to enable CCEP to make share repurchases without triggering any obligation on Olive to make a general offer for the Company.

In the Notice of Meeting, Olive has confirmed that it has no intention of changing its approach with respect to CCEP as a result of any increase in its shareholding due to any share repurchase. It has no intention to seek any change in the composition of the Board or to the general nature or any other aspect of the Company's business. Given Olive's stated position, we believe that any concerns over "creeping control" are therefore unfounded.

As noted above, a share repurchase will not occur unless Resolution 21 is approved.

The CCEP Board and management firmly believe these resolutions are in the best interests of shareholders as they provide the ability to repurchase shares, enabling CCEP to continue to deliver long-term shareholder value. Accordingly, the Board and management of CCEP recommend voting "FOR" Resolutions 21, 23 and 24, consistent with the recommendation of Glass Lewis.

Resolutions 9 and 16 (re-election of Irial Finan and Mario Rotllant Solá, respectively)

The report issued by Glass Lewis recommends voting "FOR" Resolution 9 (the re-election of Irial Finan) and Resolution 16 (the re-election of Mario Rotllant Solá). The report states:

"We note that Olive Partners, S.A. ("Olive") and European Refreshments beneficially hold approximately 36.58% and 19.01%, respectively, of the Company's issued share capital.

We generally believe that persons or entities with a significant portion of the Company's voting power should be entitled to representation in proportion to its ownership interest on the Company's board and committees. As such, we shall refrain from recommending against directors on a strict notion of overall board or committee independence with the exception of

the Company's audit committee.

Pursuant to the relationship agreement dated May 28, 2016, for as long Olive's beneficial ownership is at least 15%, the remuneration committee will be required to include at least one director nominated by them. In addition, for as long as European Refreshments' beneficial ownership is at least 10%, the remuneration committee will be required to include at least one director nominated by them. Further, the terms of the relationship agreement provides that all directors will be elected annually, other than the initial independent NEDs and the initial chair, who have longer initial terms.

Having reviewed the nominees, we do not believe there are substantial issues for shareholder concern."

The report generated by ISS notes that its policy requires remuneration committees to be comprised solely of independent directors. It therefore recommends a vote "AGAINST" the re-election of the two non-independent members of CCEP's Remuneration Committee.

The CCEP Board and the Remuneration Committee Chairman, Christine Cross, are of the opinion that the re-election of Mr. Finan and Mr. Rotllant Solá is appropriate because:

• the Remuneration Committee comprises a majority of Independent Non-executive Directors (INEDs), notwithstanding the presence of Mr. Finan and Mr. Rotllant Solá;

• the terms of reference of the Remuneration Committee stipulate that it must be composed of a majority of INEDs, including for quorum requirements; and

• Mr Finan and Mr. Rotllant Solá are not executive directors, but appointed representatives of the Company's largest shareholders - it is natural that these shareholders would want a say on the remuneration of senior executives.

The CCEP Board and management firmly believe these resolutions are in the best interests of shareholders and recommend voting "FOR" Resolutions 9 and 16, consistent with the recommendation of Glass Lewis.

We would be glad to discuss the CCEP recommendations in relation to Resolutions 21, 9 and 16 further with you, should you wish. If you have any questions, or need assistance in submitting your proxy to vote your shares, please contact us at shareholders@ccep.com.

Thank you for your support.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCKKPBNFBKKPPD
Date   Source Headline
10th May 20247:00 amRNSLetter to Shareholders
3rd May 20247:00 amRNSResignation of Chief Financial Officer
1st May 20243:00 pmRNSTotal Voting Rights
25th Apr 20247:00 amRNSQ1 Trading Update & Interim Dividend Declaration
24th Apr 20241:30 pmRNSDirector/PDMR Shareholding
17th Apr 20241:45 pmRNSDirector/PDMR Shareholding
10th Apr 20249:15 amRNSNotice of AGM
2nd Apr 20242:30 pmRNSTotal Voting Rights
21st Mar 20242:00 pmRNSDirector/PDMR Shareholding
20th Mar 20243:00 pmRNSDirector/PDMR Shareholding
18th Mar 20244:30 pmRNSBlock listing Interim Review
15th Mar 202411:59 amRNSAnnual Financial Report
1st Mar 20242:00 pmRNSTotal Voting Rights
23rd Feb 20247:00 amRNSCompletion of joint acquisition of CCBPI
23rd Feb 20247:00 amRNSPreliminary Unaudited Results Q4 & FY 2023
21st Feb 20245:00 pmRNSDirector/PDMR Shareholding
1st Feb 20242:30 pmRNSTotal Voting Rights
30th Jan 202411:30 amRNSPCC approval received to jointly acquire CCBPI
26th Jan 20244:15 pmRNSDirector/PDMR Shareholding - amendment
25th Jan 202410:30 amRNSDirector/PDMR Shareholding
22nd Jan 20243:15 pmRNSDirector/PDMR Shareholding
17th Jan 202411:30 amRNSDirector/PDMR Shareholding
2nd Jan 20241:30 pmRNSTotal Voting Rights
20th Dec 202311:15 amRNSDirector/PDMR Shareholding
18th Dec 202312:15 pmRNSDirector/PDMR Shareholding
15th Dec 20233:40 pmRNSDirector/PDMR Shareholding
14th Dec 202311:00 amRNSDirectorate Change
1st Dec 20231:45 pmRNSTotal Voting Rights
28th Nov 20234:00 pmRNSDirector/PDMR Shareholding
24th Nov 20232:30 pmRNSUpdate statement on 2023 AGM voting results
21st Nov 20234:30 pmRNSDirector/PDMR Shareholding
20th Nov 20237:00 amRNSUpdate re acquisition of CCBPI
1st Nov 20231:45 pmRNSTotal Voting Rights
1st Nov 20237:00 amRNSQ3 Trading Update & Interim Dividend Declaration
25th Oct 20231:30 pmRNSDirector/PDMR Shareholding
20th Oct 202312:00 pmRNSDirector/PDMR Shareholding
13th Oct 20232:30 pmRNSDirector/PDMR Shareholding
20th Sep 20234:45 pmRNSDirector/PDMR Shareholding
18th Sep 20234:50 pmRNSBlock listing Interim Review
1st Sep 20231:30 pmRNSTotal Voting Rights
22nd Aug 20233:00 pmRNSDirector/PDMR Shareholding
2nd Aug 20237:01 amRNSResults for the six months ended 30 June 2023
2nd Aug 20237:00 amRNSProposed joint acquisition of CCBPI
1st Aug 20231:05 pmRNSTotal Voting Rights
25th Jul 20234:00 pmRNSDirector/PDMR Shareholding
21st Jul 20232:30 pmRNSDirector/PDMR Shareholding
13th Jul 20233:30 pmRNSDirector/PDMR Shareholding
30th Jun 20234:30 pmRNSDirector/PDMR Shareholding
23rd Jun 20233:00 pmRNSDirector/PDMR Shareholding
8th Jun 202310:50 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.